The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.52BCNY
610.59M · vs all stocks (USD)
Updated Nov 22, 2026
Revenue (TTM)
1.27BCNY
174.39M · vs all stocks (USD)
Updated Nov 22, 2026
Profit Margin
-0.55%
vs Biotechnology peers
Updated Nov 22, 2026
Beta
0.7810x
vs all stocks
Updated Nov 22, 2026
52-Week Change
-32.10%
vs all stocks
Updated Nov 22, 2026
Market Capitalization
3.52BCNY
610.59M · vs all stocks (USD)
Updated Nov 22, 2026
Enterprise Value
3.60BCNY
610.34M · vs all stocks (USD)
Updated Nov 22, 2026
Forward P/E
17.45x
vs Biotechnology peers
Updated Nov 22, 2026
Price to Sales (TTM)
2.75x
vs Biotechnology peers
Updated Nov 22, 2026
Price to Book (MRQ)
2.65x
vs Biotechnology peers
Updated Nov 22, 2026
Enterprise to Revenue
2.85x
vs Biotechnology peers
Updated Nov 22, 2026
Enterprise to EBITDA
55.51x
vs Biotechnology peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 21.48×.Updated Nov 22, 2026
Gross Margin
25.02%
vs Biotechnology peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 27.43%.Updated Nov 22, 2026
Profit Margin
-0.55%
vs Biotechnology peers
Updated Nov 22, 2026
Operating Margin
1.80%
vs Biotechnology peers
Updated Nov 22, 2026
Return on Assets (TTM)
0.69%
vs Biotechnology peers
Updated Nov 22, 2026
Return on Equity (TTM)
-0.52%
vs Biotechnology peers
Updated Nov 22, 2026
Revenue (TTM)
1.27BCNY
174.39M · vs all stocks (USD)
Updated Nov 22, 2026
Revenue per Share (TTM)
2.83CNYUpdated Nov 22, 2026
Quarterly Revenue Growth
36.00%
vs Biotechnology peers
Updated Nov 22, 2026
Gross Profit (TTM)
347.05MCNY
46.66M · vs all stocks (USD)
Updated Nov 22, 2026
EBITDA (TTM)
167.83MCNY
25.16M · vs all stocks (USD)
Updated Nov 22, 2026
Net Income (TTM)
-7.00MCNY
-6.44M · vs all stocks (USD)
Updated Nov 22, 2026
Quarterly Earnings Growth (YoY)
13.21%
vs Biotechnology peers
Updated Nov 22, 2026
Operating Cash Flow (TTM)
171.42MCNY
24.75M · vs all stocks (USD)
Updated Nov 22, 2026
Levered Free Cash Flow (TTM)
9.81MCNY
5.83M · vs all stocks (USD)
Updated Nov 22, 2026
5-Year Average Dividend Yield
0.29%
vs all stocks
Updated Nov 22, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Updated Nov 22, 2026
Minority Interest (Equity)
24.34MCNYFY2025 · Dec 31, 2025
Revenue
1.13BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
810.03MCNYFY2025 · Dec 31, 2025
Gross Profit
324.69MCNYFY2025 · Dec 31, 2025
Operating Income
39.10MCNY
5.86M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
16.01MCNYFY2025 · Dec 31, 2025
Income Tax Expense
2.46MCNYFY2025 · Dec 31, 2025
Net Income
13.55MCNYFY2025 · Dec 31, 2025
EBIT
31.88MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
167.83MCNYFY2025 · Dec 31, 2025
Research & Development
59.84MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
94.98MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
4.20MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
9.86MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
15.86MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.0300CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.0300CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
447.07MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
447.07MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
13.55MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
-140.89KCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-12.12MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-74.41MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
405.48MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
13.55MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
64.68MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-89.40MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-957.65KCNYFY2025 · Dec 31, 2025
Capital Expenditures
-62.29MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-21.65MCNYFY2025 · Dec 31, 2025
Sale of Investments
60.25MCNYFY2025 · Dec 31, 2025
Other Investing Activity
-46.22MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-69.90MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
21.00MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-47.53MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-2.90MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-50.28MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-79.71MCNYFY2025 · Dec 31, 2025
Shares Outstanding
497.96MSharesUpdated Nov 22, 2026
Float Shares
311.22MSharesUpdated Nov 22, 2026
% Held by Insiders
29.39%
vs all stocks
Updated Nov 22, 2026
% Held by Institutions
1.68%
vs all stocks
Updated Nov 22, 2026
Total Cash (MRQ)
440.17MCNY
61.17M · vs all stocks (USD)
Updated Nov 22, 2026
Total Cash per Share (MRQ)
0.8720CNYUpdated Nov 22, 2026
Total Debt (MRQ)
490.23MCNY
63.71M · vs all stocks (USD)
Updated Nov 22, 2026
Total Debt to Equity (MRQ)
0.3608x
vs Biotechnology peers
Updated Nov 22, 2026
Current Ratio (MRQ)
1.99x
vs Biotechnology peers
Updated Nov 22, 2026
Book Value per Share (MRQ)
2.63CNYUpdated Nov 22, 2026
Total Assets
2.03BCNY
304.74M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
765.02MCNYFY2025 · Dec 31, 2025
Total Liabilities
732.59MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
1.27BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
377.14MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
355.45MCNYFY2025 · Dec 31, 2025
Cash
405.45MCNYFY2025 · Dec 31, 2025
Cash Equivalents
6.38MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
411.83MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
45.57MCNYFY2025 · Dec 31, 2025
Accounts Receivable
229.26MCNYFY2025 · Dec 31, 2025
Inventory
9.47MCNYFY2025 · Dec 31, 2025
Accounts Payable
50.31MCNYFY2025 · Dec 31, 2025
Short-term Debt
135.22MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
1.02MCNYFY2025 · Dec 31, 2025
Long-term Debt
333.95MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
13.57MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
497.96MCNYFY2025 · Dec 31, 2025
Retained Earnings
-667.16MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.30BCNY
194.92M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
6.98CNYUpdated Nov 22, 2026
52-Week High
14.23CNYUpdated Nov 22, 2026
52-Week Change
-32.10%
vs all stocks
Updated Nov 22, 2026
Beta
0.7810x
vs all stocks
Updated Nov 22, 2026
50-Day MA
8.80CNYUpdated Nov 22, 2026
200-Day MA
9.56CNYUpdated Nov 22, 2026
Avg 10-Day Volume
14.92MSharesUpdated Nov 22, 2026
Avg 30-Day Volume
21.85MSharesUpdated Nov 22, 2026
Diluted EPS (TTM)
-0.0100CNYUpdated Nov 22, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.73: safe zoneNotable
Altman Z-Score: 3.73
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.